Skip to content

Corneal Epithelial Wound Healing Difference Between Human Autoserum and Cord Blood Serum

Phase 1 Study of Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Autoserum and Cord Blood Serum-in Vitro Cell Culture Experiment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00681642
Enrollment
7
Registered
2008-05-21
Start date
2007-03-31
Completion date
2008-03-31
Last updated
2011-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Epithelial Wound Healing

Keywords

Corneal epithelial wound, Human autoserum, Cord blood

Brief summary

Human serum eye drops have been successfully used in the treatment of severe ocular surface disorders and the enhancement of corneal wound healing. Umbilical cord serum is also proven to be effective in treatment of dry eye and persistent corneal epithelial defects. However, there are limited studies comparing the corneal epithelial wound healing promoting effects between these two blood derived products. The purpose of this study is to test the corneal epithelial wound healing promoting effects between auto serum and human cord blood serum. Primary cultured bovine corneal epithelial cells were used as the model to investigate wound healing, cell proliferation and migration by means of scratch corneal wound healing assay evaluation, MTS assay and Boyden chamber migration assay in response to human serum and umbilical cord serum. The concentrations of EGF, TGF-β1, and fibronectin were also compared between human serum and umbilical cord serum with ELISA kits.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Healthy pregnant women * Cesarean section for labor * Complete placenta with umbilical cord retained * Healthy individual

Exclusion criteria

* The retained placenta and umbilical cord were not complete * Individual with anemia or other hematologic disorder unsuitable for blood donation

Design outcomes

Primary

MeasureTime frame
Cell proliferation1 week

Secondary

MeasureTime frame
Cell migration1 week

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026